SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending following the announcement of a $9.7 billion AI cloud services contract with Microsoft, including a substantial prepayment. The community is buzzing about the potential impact of this deal, which involves providing access to NVIDIA GB300 GPUs, and speculating on whether this positions IREN as a major player in AI infrastructure. Some traders are debating whether to take profits, while others are eagerly anticipating further gains and potential deals.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining ($CIFR) is trending amid bullish sentiment fueled by a recent $5.5B AWS deal, with traders actively discussing the company's shift towards AI infrastructure and potential for further expansion. Community members highlight positive earnings and revenue forecasts, viewing $CIFR as a key player in the growing AI datacenter landscape alongside peers like $IREN. Some investors are also anticipating a possible deal with Black Pearl soon.

Mannatech, Inc. engages in the development of nutritional supplements, topical and skin care products and weight-management products that target optimal health and wellness. Its product category includes integrative health, targeted health, wealth and fitness, skin care, essentials, and home. The company was founded by Marlin Ray Robbins and Samuel L. Caster in November 1993 and is headquartered in Flower Mound, TX.

Mannatech Inc

MTEX is trending due to its low float, with traders actively discussing its potential for a significant upward move. Community members are pointing to the stock's history of past runs and are watching for a break above key resistance levels. Some traders are expressing caution, suggesting the move may be a pump and dump.

Kenvue, Inc. is a consumer health company, which engages in manufacturing and selling healthcare products which includes cosmetics, drugs, and medical devices. Its brands include Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol. It operates through the following segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care, and others. The Essential Health segment focuses on oral care, baby care, women's health, and wound care. The company was founded on February 23, 2022 and is headquartered in Summit, NJ.

Kenvue Inc

Kenvue ($KVUE) is trending as investors react to news of Kimberly-Clark ($KMB) acquiring the company in a deal valued at $48.7 billion, with shareholders set to receive cash and stock. The community is discussing the implications of the buyout, potential competing bids, and the value of KMB shares as they relate to the deal's overall worth.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure ($QURE) is trending due to a significant regulatory update concerning its Huntington's disease treatment, AMT-130. The FDA's revised stance on the data requirements for approval has sparked community debate about the future of the drug and the company's strategy. Discussions also include speculation about potential buyouts and the implications for the broader biotech sector.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending as investors discuss the company's potential revenue growth following recent earnings and future projections, especially the possibility of reaching $1 billion in 2026. The community is focused on whether upcoming catalysts, such as the potential launch of a new dosing regimen in 2027 and commercialization outside the US, will drive the stock towards a $10 billion market cap. Some traders are speculating on a potential buyout and how Neuraxpharm may factor into future decisions.

Kimberly-Clark Corp. engages in the manufacture and marketing of products made from natural or synthetic fibers. It operates through the following segments: North America, International Personal Care, and International Family Care and Personal. The North America segment consists of products encompassing each of daily-need categories across consumer and professional channels including disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear, facial and bathroom tissue, paper towels, napkins, wipers, tissue, towels, soaps and sanitizers and other related products. The International Personal Care segment consists of three core categories: Baby & Child Care, Adult Care, and Feminine Care, including disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear and other related products. The International Family Care and Professional segment consists of two core categories: Family Care and Professional, including facial and bathroom tissue, paper towels, napkins, wipers, tissue, towels, soaps and sanitizers and other related products. The company was founded by John A. Kimberly, Havilah Babcock, Charles B. Clark, and Frank C. Shattuck in 1872 and is headquartered in Irving, TX.

Kimberly-Clark Corp.

Kimberly-Clark's stock is trending following news of its agreement to acquire Kenvue in a deal valued at $48.7 billion, triggering mixed reactions from the community. While some investors see long-term value and free cash flow potential, others express concern over potential lawsuits tied to Kenvue and the overall deal terms, contributing to active debate.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending as investors anticipate upcoming earnings, with discussions focused on whether the company can justify its high valuation amidst AI sector growth. Community members are debating potential catalysts like new contracts and a possible stock split, while some express concern about the stock's high P/E ratio and potential for a post-earnings dip. The company's positioning in government and commercial sectors, along with its AI capabilities, remains a key talking point.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending as the community grapples with the aftermath of a recent lawsuit against a former FDA official and his subsequent resignation, with shareholders debating potential buyout scenarios and the impact on share value. Community members are actively discussing the lawsuit's allegations of bribery and defamation and also earnings call, alongside speculation about the company's future direction and potential for a buyout. The conversations highlight the stock's volatility and the community's intense focus on corporate actions and external influences.

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

$SLAP is trending, driven by community enthusiasm and discussions around its potential. The coin's active community emphasizes building and long-term vision, using the phrase "WAGMI" (We Are All Going to Make It) to show their collective belief. Conversations often highlight the coin's real-world partnerships.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

GILD Q3 Earnings and Sales Beat Estimates, HIV and Livdelzi Sales Grow 

Gilead posts upbeat Q3 results on strong HIV and Livdelzi sales, but shares slip despite earnings and revenue beats.

Insmed Misses on Q3 Earnings, Stock Rises on Strong Brinsupri Uptake

INSM shares jump 16% as Brinsupri's strong debut offset wider Q3 losses, lifting revenue 52% year over year.

BMY Beats on Q3 Earnings and Sales, Raises 2025 Sales View

Bristol-Myers' strong Q3 results, powered by Opdivo, Reblozyl and Breyanzi, led to a revenue guidance boost despite legacy drug declines.

BHC Stock Up on Q3 Earnings Beat, Salix and Solta Drive Sales 

Bausch Health's Q3 results top expectations as strong Salix and Solta sales fuel growth. Shares gain.

Alkermes Q3 Earnings and Revenues Beat Estimates, 2025 View Raised

ALKS tops Q3 earnings and revenue estimates as Vivitrol, Aristada and Lybalvi fuel growth; 2025 guidance raised after strong demand.

BioMarin Beats on Q3 Earnings, Seeks to Divest Hemophilia Gene Therapy

BMRN tops Q3 earnings expectations but misses on sales. The company moves to divest its hemophilia gene therapy, Roctavian.

Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say

The headline numbers for Alkermes (ALKS) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates

Alkermes (ALKS) delivered earnings and revenue surprises of +16.67% and +10.83%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Alkermes plc Reports Third Quarter 2025 Financial Results

Alkermes plc Reports Third Quarter 2025 Financial Results Alkermes plc Reports Third Quarter 2025 Financial Results PR Newswire DUBLIN, Oct. 28, 2025 Third Quarter Revenues of $394.2 Million GAAP Net...

Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales Nil

VKTX posts a wider Q3 loss and no sales, as R&D costs surge and obesity drug studies drive spending higher.

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

Alkermes plc

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$0.42	--	--	N/A
Q3 '25	$0.37	$0.68	84.71%	BEAT
Q2 '25	$0.36	$0.67	87.91%	BEAT
Q1 '25	$0.25	$0.27	4.20%	BEAT
Q4 '24	$0.76	$1.05	38.26%	BEAT

ALKS
Alkermes plc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest ALKS News

ALKSAlkermes plc